- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Reduce gap between second and Covid booster dose from 9 to 6 months, recommends NTAGI
The STSC members were learnt to have also agreed on administration of an additional third dose for renal transplant patients before the precaution dose.
New Delhi: Members of the government advisory panel NTAGI on Thursday agreed on reducing the gap between the second and precaution doses of COVID-19 vaccines from the current nine to six months, official sources said.
A recommendation for it will be made to the Health Ministry soon, they said.
The NTAGI's Standing Technical Sub-Committee (STSC), which met on Thursday, also reviewed the findings of a study by the Christian Medical College (CMC) in Vellore on the feasibility of allowing a precaution dose of a Covid vaccine different from the one used for primary vaccination.
The panel members found a lack of uniformity in results upon mixing of jabs for booster shots and stated that no recommendation for it can be made as of now. The CMC study was on Covishield and Covaxin.
The threat of monkeypox and the requirement of vaccination were also discussed in the meeting, the sources said.
"However, the members were of the view that a strong surveillance is what is required as of now. No case of monkeypox has been detected in the country till now," one of the sources told PTI.
The panel also reviewed data on Covaxin and Corbevax vaccines for the 6-12 age group.
"The members opined that data of Covid burden and mortality among children is not robust enough to take any decision to begin vaccination of those below 12 years," the source stated.
India's drug regulator in April this year had granted emergency use authorisation for Biological E's COVID-19 vaccine Corbevax for those aged five to 12 years and Bharat Biotech's Covaxin for children in the age group of six to 12 years.
The STSC members were learnt to have also agreed on administration of an additional third dose for renal transplant patients before the precaution dose.
"In the meeting today, members also agreed on reducing the gap between the second and the precaution doses of COVID-19 vaccines from the current nine months to six months," the source told PTI.
Currently, all those above the age of 18 who have completed nine months after the administration of the second dose are eligible for the precaution dose.
The Union government last month allowed citizens and students travelling overseas to get the shot before the stipulated nine-month waiting period as required by the guidelines of the destination country.
Read also: NTAGI recommends coronavirus precaution dose before 9 months for those travelling abroad
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751